Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy

被引：4
|
作者：
Breccia, Massimo [1 ]
Santopietro, Michelina [1 ]
Loglisci, Giuseppina [1 ]
Stagno, Fabio [2 ,3 ]
Cannella, Laura [1 ]
Carmosino, Ida [1 ]
Alimena, Giuliana [1 ]
机构：
[1] Dept Human Biotechnol & Hematol, I-00161 Rome, Italy
[2] Univ Catania, Dept Biomed Sci, Hematol Sect, Catania, Italy
[3] Univ Catania, Gen Pathol Sect, Catania, Italy
来源：
LEUKEMIA RESEARCH | 2010年 / 34卷 / 08期
关键词：
Chronic myeloid leukemia; Imatinib; Warfarin;
D O I：
10.1016/j.leukres.2010.03.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E224 / E225
页数：2
相关论文
共 50 条
  • [31] Current use of imatinib in the treatment of chronic myeloid leukemia
    O'Dwyer, M
    HAEMATOLOGICA, 2003, 88 (03) : 241 - 244
  • [32] Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase
    Bittencourt, H.
    Funke, V.
    Fogliatto, L.
    Magalhaes, S.
    Setubal, D.
    Paz, A.
    Macedo, A. V.
    Ruiz, J.
    Azambuja, A. P.
    Silla, L.
    Clementino, N.
    Pasquini, R.
    BONE MARROW TRANSPLANTATION, 2008, 42 (09) : 597 - 600
  • [33] Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
    Rudzki, Jakob
    Wolf, Dominik
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (02) : 153 - 159
  • [34] Efficacy and safety of imatinib treatment in elederly patients with chronic myeloid leukemia.
    Martino, B
    Vincelli, L
    Ronco, F
    Modafferi, B
    Princi, D
    Morabito, F
    Izzo, B
    Pane, F
    Nobile, F
    BLOOD, 2004, 104 (11) : 254B - 254B
  • [35] Imatinib mesylate in newly diagnosed patients of chronic myeloid leukemia chronic phase: A comparative study
    Jacob, L. A.
    Bapsy, P. P.
    Govindbabu, K.
    Lokanatha, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase
    H Bittencourt
    V Funke
    L Fogliatto
    S Magalhães
    D Setubal
    A Paz
    A V Macedo
    J Ruiz
    A P Azambuja
    L Silla
    N Clementino
    R Pasquini
    Bone Marrow Transplantation, 2008, 42 : 597 - 600
  • [37] Outcome of Chronic Myeloid Leukemia-Chronic Phase Patients Treated With Imatinib: A Local Experience
    Al-Amri, Ali M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (03): : 199 - 203
  • [38] Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase
    Rumpel, M
    Friedrich, T
    Deininger, MWN
    BLOOD, 2003, 101 (11) : 4641 - 4643
  • [39] Safety and Efficacy of Flumatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Imatinib
    Liu, Yuntao
    Yang, Yunfan
    Sun, Hui
    Meng, Li
    Lin, Hai
    Chen, Chunyan
    Hu, Jianda
    Shen, Xuliang
    Duan, Minghui
    Zhang, Yanli
    Abulaiti, Dilinazi
    Wang, Jinghua
    Zhu, Hongqian
    Hua, Luoming
    Leng, Qing
    Zhang, Chun
    Sun, Lili
    Li, Weiming
    Zhu, Huanling
    Liu, Bingcheng
    Wang, Jianxiang
    BLOOD, 2023, 142
  • [40] Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia
    Akiyoshi Takami
    Shigeki Ohtake
    Eriko Morishita
    Yasushi Terasaki
    Toshihiro Fukushima
    Toshiro Kurokawa
    Naomi Sugimori
    Sadaya Matano
    Kinya Ohata
    Chizuru Saito
    Masaki Yamaguchi
    Kohei Hosokawa
    Hirohito Yamazaki
    Yukio Kondo
    Shinji Nakao
    International Journal of Hematology, 2012, 96 : 357 - 363
12345